FDA approves Eli Lilly’s tirzepatide for obesity, paving way for even wider use of blockbuster drug
The obesity approval further establishes Eli Lilly as a formidable competitor to Novo Nordisk in the budding weight loss drug
Read MoreThe obesity approval further establishes Eli Lilly as a formidable competitor to Novo Nordisk in the budding weight loss drug
Read MoreU.S. crude oil prices fall below $78 a barrel to their lowest since July Source link
Read MoreNovo Nordisk said its blockbuster weight-loss drug Wegovy could receive expanded approval from the U.S. Food and Drug Administration within
Read MoreWorkers are concerned that Walgreens and CVS are placing unreasonable demands on them, without providing enough resources to safely execute
Read MoreMerck's revenue and earnings beat expectations, and it hiked its sales forecast while lowering its profit outlook. Source link
Read MoreEisai and Biogen said in a release that they plan to apply for U.S. approval of subcutaneous Leqembi by the
Read MoreMike Johnson was elected unanimously by the 220 Republicans who voted, despite being the fourth nominee tapped by the fractious
Read MoreIt marks J&J's first quarterly results since the company completed the separation from its consumer health spinoff Kenvue in August.
Read MoreTwo experts see major challenges facing the adoption of Novo Nordisk and Eli Lilly's obesity drugs. Source link
Read More